digital health investing

In March, the company received FDA marketing authorization for the first at-home test to detect chlamydia, gonorrhea and trichomoniasis.

The company's valuation has increased by $1 billion since its $130 million Series E funding round last year.

Maite Malet, Asabys Partners director of investments and corporate development, discusses the Barcelona-based firm’s €180 million ($200 million) raise and its plans invest in 12 to 15 health tech companies to expand from the EU to the U.S.